INNA 051
Alternative Names: INNA-051Latest Information Update: 03 Sep 2026
At a glance
- Originator Ena Respiratory
- Class Antivirals; Small molecules
- Mechanism of Action Toll-like receptor 2 agonists; Toll-like receptor 6 agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Influenza virus infections
- Phase I Viral infections
- Preclinical Asthma
Most Recent Events
- 01 Sep 2026 Preclinical trials in Asthma in Australia (Intranasal), prior to September 2026
- 01 Sep 2026 Pharmacodynamics data from preclinical trial in Asthma released by ENA Respiratory
- 01 Sep 2026 ENA Respiratory plans phase Ib ENA-A-04 trial in Asthma (In adults) in quarter one of 2027 (intranasal)